To investigate the response to PARPi in Brca1-deficient breast cancer, we developed a syngeneic GEMM driven by concurrent ablation of Brca1 and Trp53 (referred as BP), as protein-truncating TP53 mutations are frequently found in BRCA1-deficient breast cancers28. Here, TP53 is linked to breast cancer.